Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc) (OBI)
Occult Hepatitis B, Liver Transplant; Complications
About this trial
This is an interventional treatment trial for Occult Hepatitis B focused on measuring occult hepatitis b, liver transplantation, novel biomarkers
Eligibility Criteria
Inclusion Criteria:
- 1. Patient age ≥18 years undergoing liver transplantation
- 2. Donor HBsAg- and anti-HBc+
Exclusion Criteria:
- 1. Recipient of multiple solid organ transplants
- 2. Patient undergoing re-transplantation
Sites / Locations
- The University of Hong KongRecruiting
Arms of the Study
Arm 1
Other
HBsAg-negative recipients
Recipients who are HBsAg-negative will undergo a panel of test to detect HBV viral markers. In addition, real-time PCR will be used to determine the presence of intrahepatic HBV DNA and cccDNA on the explant histology. Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis. For those without evidence of OBI, that is, negative for all biomarkers, no antiviral prophylaxis will be given.